JP2016517843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517843A5 JP2016517843A5 JP2016504370A JP2016504370A JP2016517843A5 JP 2016517843 A5 JP2016517843 A5 JP 2016517843A5 JP 2016504370 A JP2016504370 A JP 2016504370A JP 2016504370 A JP2016504370 A JP 2016504370A JP 2016517843 A5 JP2016517843 A5 JP 2016517843A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- acceptable salt
- compound
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 101150099493 STAT3 gene Proteins 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 11
- 239000013078 crystal Substances 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000005962 mycosis fungoides Diseases 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000003739 neck Anatomy 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 210000003932 urinary bladder Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 108010058546 Cyclin D1 Proteins 0.000 claims description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 2
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 206010061309 Neoplasm progression Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 241000282695 Saimiri Species 0.000 claims description 2
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 2
- 208000021388 Sezary disease Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 102000000763 Survivin Human genes 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 2
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000005751 tumor progression Effects 0.000 claims description 2
- 101100480620 Arabidopsis thaliana TAT3 gene Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- -1 besylate salts Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361804613P | 2013-03-22 | 2013-03-22 | |
| US61/804,613 | 2013-03-22 | ||
| PCT/US2014/031412 WO2014153495A2 (en) | 2013-03-22 | 2014-03-21 | Novel stat3 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016517843A JP2016517843A (ja) | 2016-06-20 |
| JP2016517843A5 true JP2016517843A5 (enExample) | 2017-03-16 |
| JP6570512B2 JP6570512B2 (ja) | 2019-09-04 |
Family
ID=51581811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016504370A Expired - Fee Related JP6570512B2 (ja) | 2013-03-22 | 2014-03-21 | 新規なＳｔａｔ３阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9802888B2 (enExample) |
| EP (1) | EP2975936A4 (enExample) |
| JP (1) | JP6570512B2 (enExample) |
| WO (1) | WO2014153495A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105120854B (zh) * | 2012-05-25 | 2019-04-09 | 多伦多大学管理委员会 | 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 |
| US10519107B2 (en) | 2014-05-30 | 2019-12-31 | The Governing Council Of The University Of Toronto | Sulfonamide compounds and their use as STAT5 inhibitors |
| US20180072815A1 (en) | 2014-10-23 | 2018-03-15 | Singh Biotechnology, Llc | Single Domain Antibodies Directed Against Intracellular Antigens |
| MX379450B (es) * | 2014-10-23 | 2025-03-11 | Singh Biotechnology Llc | Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares |
| CN111356456A (zh) * | 2017-01-23 | 2020-06-30 | 夏威夷大学 | 2-芳基磺酰胺基-iV-芳基乙酰胺衍生的Stat3抑制剂 |
| EP3501511A1 (en) | 2017-12-22 | 2019-06-26 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Means for preventing and treating brain metastasis |
| CN110092743B (zh) * | 2018-01-30 | 2022-03-15 | 中国医学科学院药物研究所 | 苯甲酰胺类化合物及其制备方法、用途和药物组合物 |
| WO2020018944A1 (en) * | 2018-07-20 | 2020-01-23 | Board Of Regents, The University Of Texas System | Novel stat3 inhibitors identified by structure-based virtual screening incorporating sh2 domain flexibility |
| SG11202110829YA (en) | 2019-04-05 | 2021-10-28 | Kymera Therapeutics Inc | Stat degraders and uses thereof |
| CN113754541B (zh) * | 2020-06-02 | 2025-01-03 | 深圳湾实验室 | 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JP3682584B2 (ja) * | 2001-08-06 | 2005-08-10 | ソニー株式会社 | 発光素子の実装方法及び画像表示装置の製造方法 |
| EP1934174B1 (en) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| ZA200803226B (en) | 2005-10-13 | 2009-11-25 | Orchid Res Lab Ltd | Heterocyclic Compounds as Pstat3/IL-6 Inhibitors |
| WO2009100121A1 (en) * | 2008-02-04 | 2009-08-13 | The Board Of Regents Of The University Of Oklahoma | Gamma-glutamyl transpeptidase inhibitors and methods of use |
| WO2010118309A2 (en) * | 2009-04-10 | 2010-10-14 | Board Of Regents, The University Of Texas System | Inhibitors of stat3 and uses thereof |
| US20110275577A1 (en) * | 2010-01-08 | 2011-11-10 | Moleculin, Llc | Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs |
| EP2585464A2 (en) * | 2010-06-22 | 2013-05-01 | University Of Central Florida Research Foundation, Inc. | Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3 |
| CN105120854B (zh) * | 2012-05-25 | 2019-04-09 | 多伦多大学管理委员会 | 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 |
| EA030611B1 (ru) * | 2013-03-15 | 2018-08-31 | Кэнсер Рисерч Текнолоджи, Ллк | Способы и композиции для модуляции гамма-глутамилового цикла |
-
2014
- 2014-03-21 US US14/779,276 patent/US9802888B2/en active Active
- 2014-03-21 WO PCT/US2014/031412 patent/WO2014153495A2/en not_active Ceased
- 2014-03-21 EP EP14769372.5A patent/EP2975936A4/en not_active Withdrawn
- 2014-03-21 JP JP2016504370A patent/JP6570512B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517843A5 (enExample) | ||
| JP2015533176A5 (enExample) | ||
| EP4161511A1 (en) | Novel small molecules for targeted degradation of untargetable kras in cancer therapy | |
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| JP2014533284A5 (enExample) | ||
| JP2017525730A5 (enExample) | ||
| JP2014510149A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2014513101A5 (enExample) | ||
| JP2018536636A5 (enExample) | ||
| JP2018516917A5 (enExample) | ||
| JP2018517686A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| JP2015212268A5 (enExample) | ||
| JP2021500334A5 (enExample) | ||
| JP2013189456A5 (enExample) | ||
| JP2014510729A5 (enExample) | ||
| US20130310414A1 (en) | Therapeutic or prophylactic agent for cachexia | |
| JP2015510939A5 (enExample) | ||
| JP2017524013A5 (enExample) | ||
| JP2015520770A5 (enExample) | ||
| JP2019506392A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2020506895A5 (enExample) |